Jules schreef op 7 december 2022 18:25:
HAE marktgerelateerd;
Takhzyro Wins Prix Galien Canada as 2022’s Best Innovative ProductHAE preventive therapy chosen for 'significant contribution to patient care'
Takhzyro (lanadelumab), an under-the skin injection therapy to prevent attacks in people with hereditary angioedema (HAE), has won the 2022 Prix Galien Canada Innovative Product Award.
The prestigious annual award is given to a company — here, Takeda Pharmaceuticals — in recognition of a marketed product that has “made the most significant overall contribution to patient care in Canada in terms of efficacy, safety, benefits and innovation,” Prix Galien Canada reported on a webpage.
An approved treatment of HAE swelling attacks in adults and children, Takhzyro was selected by a panel of eight academic and industry members, all with experience in pharmaceutical research in Canada